Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity

Jordan E Lake; Grace A McComsey; Todd Hulgan; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; Judith S Currier

doi:10.1093/ofid/ofv059

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity

Open Forum Infect Dis. 2015 Apr 26;2(2):ofv059. doi: 10.1093/ofid/ofv059. eCollection 2015 Apr.

Authors

Jordan E Lake¹, Grace A McComsey², Todd Hulgan³, Christine A Wanke⁴, Alexandra Mangili⁴, Sharon L Walmsley⁵, Judith S Currier¹

Affiliations

¹ Department of Medicine , University of California, Los Angeles, California.
² Department of Pediatrics and Medicine , Case Western Reserve University , Cleveland, Ohio.
³ Department of Medicine , Vanderbilt University , Nashville, Tennessee.
⁴ Department of Medicine , Tufts University , Boston, Massachusetts.
⁵ Department of Medicine , University of Toronto , Ontario , Canada.

Abstract

Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 weeks of raltegravir was associated with a 6.4% VAT decline. Raltegravir for 24 weeks was associated with improvements in lipids.

Keywords: HIV; antiretroviral therapy; fat; raltegravir; visceral; women.

Abstract

Grants and funding